Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Perspective Therapeutics (CATX) reported Q3 2025 results showing continued investment in its radiopharmaceutical pipeline. The company recorded a net loss of $25.969 million (loss per share $0.35) on $209 thousand of grant revenue. Operating expenses were driven by R&D of $20.339 million and G&A of $7.731 million, resulting in an operating loss of $27.861 million.
Liquidity remains solid with $174.1 million in cash, cash equivalents and short‑term investments as of September 30, 2025, which the company believes will fund current plans into late 2026. Year‑to‑date, operating cash outflows were $57.827 million, partially offset by $12.691 million from investing activities and $10.318 million from financing, including $9.986 million raised via the at‑the‑market program in February 2025.
Common shares outstanding were 74,337,990 as of November 6, 2025. The company continues Phase 1/2a work across VMT‑α‑NET, VMT01 and PSV359 while building out manufacturing capacity to support clinical and future commercial supply.
Perspective Therapeutics (CATX) furnished a press release announcing its financial results for the quarter ended September 30, 2025, and provided recent business highlights. The company also posted an updated corporate presentation on its website.
The press release was furnished as Exhibit 99.1 under Item 2.02, and the corporate presentation was filed as Exhibit 99.2 under Item 8.01. The Item 2.02 information is expressly not deemed “filed” under Section 18 of the Exchange Act.
FMR LLC filed Amendment No. 2 to Schedule 13G reporting a passive stake in Perspective Therapeutics (CATX). The filing shows beneficial ownership of 6,063,330 shares of common stock, representing 8.2% of the class, with a date of event of 10/31/2025.
FMR reports sole voting power over 6,057,277 shares and sole dispositive power over 6,063,330 shares, with no shared voting or dispositive power. Abigail P. Johnson is also a reporting person with beneficial ownership of 6,063,330 shares (8.2%) via dispositive power.
The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control. The filing notes that one or more other persons may have rights to dividends or sale proceeds, and that no single such person has an interest exceeding 5% of the class.
Perspective Therapeutics, Inc. (CATX) reported an administrative update: the company updated its corporate presentation. The presentation was furnished under Item 8.01 and attached as Exhibit 99.1, dated November 6, 2025.
Perspective Therapeutics (CATX) amended and restated employment agreements for its CEO Johan (Thijs) Spoor, Chief Accounting Officer Jonathan Hunt, and Chief Medical Officer Dr. Markus Puhlmann. The updates reflect current base salaries and revise change-in-control provisions.
Base salaries are $680,000 for Mr. Spoor, $451,500 for Mr. Hunt, and $516,700 for Dr. Puhlmann. If employment ends without cause or for good reason during the three months before or 12 months after a change in control, severance includes salary continuation for 12 months (18 months for Mr. Spoor), a pro‑rated target bonus, an additional amount equal to the target bonus (1.5x target for Mr. Spoor), and COBRA premiums for up to 12 months (18 months for Mr. Spoor).
Equity awards subject to time-based vesting accelerate to full vesting, and performance-based awards vest at target upon qualifying terminations in the protection period or if awards are not assumed, replaced, or continued at closing, subject to a release of claims. Other existing terms remain in effect.
Perspective Therapeutics (CATX) filed an 8‑K announcing a press release and presentation with updated interim results from its Phase 1/2a study of [212Pb]VMT‑α‑NET in patients with unresectable or metastatic SSTR2‑expressing neuroendocrine tumors. The data are being presented at ESMO 2025 in Berlin. The materials also include the Company’s estimated cash, cash equivalents and short‑term investments as of September 30, 2025, which are preliminary, unaudited, and subject to change.
Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation. The updated presentation, dated October 1, 2025, is furnished as Exhibit 99.1 to the report and incorporated by reference into the other events section.
Perspective Therapeutics insider Joel Sendek, the company's Chief Financial Officer, was granted a stock option on 09/04/2025 to purchase 600,000 shares of common stock at an exercise price of $3.54 per share. The option has an expiration date of 09/04/2035 and becomes exercisable over a four-year vesting schedule: one-fourth vests on 09/04/2026 and the remaining shares vest ratably over the following 36 months, subject to continuous service. After the grant, the reporting person beneficially owns 600,000 underlying shares through the option, held in a direct ownership form. The Form 4 was signed by attorney-in-fact on 09/05/2025.
Joel Sendek, serving as Chief Financial Officer and a director of Perspective Therapeutics, Inc. (CATX), filed an initial Form 3 reporting the 09/04/2025 event date. The filing states that the reporting person does not beneficially own any securities of the issuer. The form references Exhibit 24 (Power of Attorney) and was signed via attorney-in-fact on 09/05/2025.
Maria E. Martinez, a director of Perspective Therapeutics, Inc. (CATX), was granted 75,000 stock options on 09/03/2025 with an exercise price of $3.38. The options vest monthly over three years in 36 substantially equal installments beginning one month after the grant date, are exercisable beginning 09/03/2025, and expire on 09/03/2035. After the reported transaction the reporting person beneficially owns 75,000 shares underlying the option on a direct basis. The Form 4 was signed on behalf of Maria E. Martinez by an attorney-in-fact on 09/05/2025.